Pluristem Granted European Patent for Use of Cells to Help

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pluristem Granted European Patent for Use of Cells to Help Treat Damaged Bone Marrow

HAIFA, Israel, May 6, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq: PSTI ) (TASE: PLTR ), a leading developer of placenta-based cell therapy products, announced today that it has been issued Patent No. EP2366775B1, titled "Methods for Cell Expansion and Uses of Cells and Conditioned Media Produced Thereby for Therapy", by the European Patent Office. This patent addresses use of adherent stromal cells from placenta or adipose tissue, expanded according to Pluristem's methods of three dimensional culturing, for treating conditions that may benefit from facilitation of hematopoietic stem cell engraftment. As described in the patent, Pluristem's therapeutic cells are designed to promote the success of hematopoietic stem cell transplantation, which is used to treat patients with dysfunctional bone marrow. The damage to the bone marrow could be due to chemotherapy or exposure to high levels of radiation, such as can occur as part of treatment for certain cancers or in a nuclear catastrophe.  

Successful facilitation of hematopoietic stem cell engraftment is demonstrated by an increase in the number of bone marrow cells that are responsible for producing the cells which circulate in the blood (white blood cells, red blood cells and platelets). These circulating cells are required to resist infection, transport oxygen within the body, and prevent hemorrhage.

"This patent strengthens our position in the hematologic space, and will support an anticipated clinical program for our PLX-R18 cells in the treatment of damaged bone marrow. Since damage to bone marrow can result from a range of illnesses and exposures, we hope that our product will be able to benefit many patients suffering from hard-to-treat conditions," stated Pluristem CEO Zami Aberman. To date, Pluristem has been issued over 35 patents, and has approximately 150 more patents pending worldwide.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company's patented PLX (PLacental eXpanded) cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cells are grown using the Company's proprietary three-dimensional expansion technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, Company-owned, GMP-certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com , the content of which is not part of this press release.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws.  For example, forward-looking statements are used in this press release when we discuss our plan to begin clinical trials of our PLX-R18 cells for help with treatment of damaged bone marrow, and our hope that our product will be able to benefit many patients suffering from hard-to-treat conditions. These forward-looking statements and their implications are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

Pluristem Therapeutics Inc.: Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 66

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 90

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 81

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 71

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 124

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 58

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 67

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 20

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 146

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading

Top 5 Most Recently Viewed Articles

Estimating the Growth of $100 in Webster Financial Shares

Updated Category News Views 237

Understanding Webster Financial's Long-Term Growth Webster Financial, trading under the symbol WBS, has demonstrated a remarkable performance in the stock market over the past five years. The investment landscape can be unpredictable, but looking at WBS, we can observe that it has outperformed the market by an average of 3.91% annually, yielding a total annual return of...

Continue Reading
Grocery Outlet Shareholders Can Pursue Securities Fraud Claims

Updated Category News Views 129

Grocery Outlet Shareholders Can Pursue Securities Fraud Claims Investors have the chance to reclaim their losses after allegations of securities fraud at Grocery Outlet Holding Corp. (NASDAQ: GO). It’s crucial for all purchasers of Grocery Outlet securities who were active during the defined Class Period to understand their rights. Understanding the Class Period The...

Continue Reading
Core Bank Expands Services with New Banking Center Soon

Updated Category News Views 135

Core Bank Relocation to a New Overland Park Facility Core Bank is thrilled to announce its move to a new location for its Overland Park Banking Center. This relocation marks a significant milestone for the bank, allowing it to better serve the growing needs of the community. The modern banking space, set to open soon, is designed with improved accessibility and enhanced...

Continue Reading
Exploring Netflix's Recent Options Activity and Insights

Updated Category News Views 189

Netflix's Recent Options Trading Trends Financial giants have expressed a notable bullish sentiment toward Netflix. Analyzing the recent options trades for Netflix (NASDAQ: NFLX) reveals that 65 unusual trades have taken place, sparking considerable interest among investors. Traders' Sentiments and Volume Analysis Diving into the details, about 56% of traders exhibited...

Continue Reading
Simply Good Foods Faces Securities Fraud Lawsuit Turmoil

Updated Category News Views 53

Simply Good Foods: Murky Waters  Well, here we go again with yet another corporate mess. Simply Good Foods Company’s staring down a securities class action lawsuit over not-so-savory business moves that have knocked their stock into the gutter. The beef? Failing to spill the beans on troubles brewing from an acquisition that's gone south. Now, they’re facing a...

Continue Reading